(Q47316565)

13 January 2018

title

Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks (English)

1 reference

13 January 2018

0 references

Lawrence Blonde

1

1 reference

13 January 2018

Kaj Stenlöf

2

1 reference

13 January 2018

Albert Fung

3

1 reference

13 January 2018

John Xie

4

1 reference

13 January 2018

William Canovatchel

5

1 reference

13 January 2018

Gary Meininger

6

1 reference

13 January 2018

language of work or name

English

0 references

publication date

22 March 2016

1 reference

13 January 2018

published in

Postgraduate Medicine

1 reference

13 January 2018

volume

128

1 reference

13 January 2018

issue

4

1 reference

13 January 2018

page(s)

371-380

1 reference

13 January 2018

Weight management in type 2 diabetes: current and emerging approaches to treatment

cites work

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1169894

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1169894

Is there a paradox in obesity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1169894

Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1169894

2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1169894

Biological effects of bariatric surgery on obesity-related comorbidities

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1169894

The Importance of Weight Change Experiences for Performance of Diabetes Self-Care: A Patient-Centered Approach to Evaluating Clinical Outcomes in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1169894

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1169894

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1169894

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1169894

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1169894

Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1169894

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1169894

Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1169894

Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1169894

Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1169894

Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1169894

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1169894

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1169894

Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1169894

Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1169894

The impact of weight loss on weight-related quality of life and health satisfaction: results from a trial comparing canagliflozin with sitagliptin in triple therapy among people with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1169894

Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1169894

Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1169894

Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1169894

Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1169894

Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1169894

Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1169894

Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1169894

Changes in body composition over 8 years in a randomized trial of a lifestyle intervention: the look AHEAD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1169894

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1169894

Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1169894

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1169894

Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1169894

Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1169894

Quantification of the effect of energy imbalance on bodyweight

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1169894

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1169894

Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1169894

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1169894

Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1169894

Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2016.1169894

10.1080/00325481.2016.1169894

21 January 2018

Identifiers

DOI

1 reference

13 January 2018

PubMed ID

27002421

1 reference

13 January 2018